Academic Journal
The Complement System in Ovarian Cancer: An Underexplored Old Path.
| Title: | The Complement System in Ovarian Cancer: An Underexplored Old Path. |
|---|---|
| Authors: | Senent, Yaiza, Ajona, Daniel, González-Martín, Antonio, Pio, Ruben, Tavira, Beatriz |
| Source: | Cancers; Aug2021, Vol. 13 Issue 15, p3806-3806, 1p |
| Abstract: | Simple Summary: Ovarian cancer is one of the leading causes of death among women and the most lethal cause of death from gynecological malignancy in developed countries. The immune system plays an essential role in ovarian cancer progression, and its modulation may be used as an effective therapeutic tool. In this review, we examine the relevance of the cellular and humoral components of the adaptive and innate immune responses in ovarian cancer, focusing on the role of an essential component of innate immunity, the complement system. Elements of this system show tumor-promoting activities that impede the efficacy of developing treatment strategies. We discuss evidence that suggests a role of complement components in the progression of ovarian cancer and provide a rationale for evaluating the inhibition of complement components in combination with immunotherapies aimed to reactivate antitumor T-cell responses. Ovarian cancer is one of the most lethal gynecological cancers. Current therapeutic strategies allow temporary control of the disease, but most patients develop resistance to treatment. Moreover, although successful in a range of solid tumors, immunotherapy has yielded only modest results in ovarian cancer. Emerging evidence underscores the relevance of the components of innate and adaptive immunity in ovarian cancer progression and response to treatment. Particularly, over the last decade, the complement system, a pillar of innate immunity, has emerged as a major regulator of the tumor microenvironment in cancer immunity. Tumor-associated complement activation may support chronic inflammation, promote an immunosuppressive microenvironment, induce angiogenesis, and activate cancer-related signaling pathways. Recent insights suggest an important role of complement effectors, such as C1q or anaphylatoxins C3a and C5a, and their receptors C3aR and C5aR1 in ovarian cancer progression. Nevertheless, the implication of these factors in different clinical contexts is still poorly understood. Detailed knowledge of the interplay between ovarian cancer cells and complement is required to develop new immunotherapy combinations and biomarkers. In this context, we discuss the possibility of targeting complement to overcome some of the hurdles encountered in the treatment of ovarian cancer. [ABSTRACT FROM AUTHOR] |
| Subject Terms: | DISEASE progression, OVARIAN tumors, COMPLEMENT (Immunology), NEOVASCULARIZATION inhibitors, IMMUNOSUPPRESSION, CELLULAR signal transduction, CELLULAR immunity, COMBINED modality therapy, T cells, IMMUNOTHERAPY |
| Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| ISSN: | 20726694 |
| DOI: | 10.3390/cancers13153806 |
| Database: | Complementary Index |
Availability